Mim8 data sees potential as once monthly treatment for haemophilia A - European Pharmaceutical Manufacturer
Emerging drugs for hemophilia A: insights into phase II and III clinical trials
Novo Nordisk outlines strategy for revamped rare diseases unit | BioWorld
Novo Nordisk's hemophilia drug shows potential as once-monthly treatment — MedWatch
Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors - ISTH Congress Abstracts
ISTH 2022 – Novo moves forward with its Hemlibra rival | Evaluate
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys - ScienceDirect
Pharmaceuticals | Free Full-Text | Updates on Novel Non-Replacement Drugs for Hemophilia
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates
Mim8 does not affect FVIII function in hemophilia A - ISTH Congress Abstracts
Bertrand Delsuc on Twitter: "Novo Nordisk R&D milestones Q3'20 $NOVO-B semaglutide ph3 initiating next year in NASH $GMAB mim8 ph1/2 in Hemophilia A readout next year https://t.co/wdlY21E8SB" / Twitter
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Study Set to Assess Mim8 Therapy in People With Hemophilia A
A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys - Lauritzen - 2022 - Journal of Thrombosis and
